Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Ann Allergy Asthma Immunol. 2017 Feb 21;118(4):419–426. doi: 10.1016/j.anai.2017.01.007

Table 3.

Percentage of patients on no controller therapy, monotherapy, or combination therapy based on pharmacy records, described by factors significantly related to outcome based on forward selection procedurea.

None Monotherapy Combination Therapy P_OR (95% CI), p-value a

Specialty care in past 2 yrs:
Yes 0.0% 22.7% 77.3% 16.23 (6.76,39.04),p<.001
No 35.4% 39.4% 25.1% Reference
Worried about side effects of asthma medications:
Yes 34.6% 28.2% 37.2% 0.41 (0.22,0.76),p=.005
No 24.8% 40.4% 34.8% Reference
Child age:
3–4 years 35.7% 40.0% 24.3% Reference
>=5 years 24.5% 35.1% 40.4% 1.92 (1.01, 3.63), p=.046
ICU admission lifetime:
Yes 22.6% 25.8% 51.6% 2.08 (1.08,4.02),p=.029
No 30.0% 40.6% 29.4% Reference
Grass Allergy:
Positive 22.5% 30.3% 47.2% 2.29 (1.24,4.23), p=.008
Negative 34.2% 42.3% 23.4% Reference
a

P_OR=Proportional odds ratios produced from generalized ordinal regression model, adjusted for factors listed in table.